Folic Acid Supplementation in Polycythemia Vera
Yes, you should recommend folic acid supplementation for patients with polycythemia vera on hydroxyurea and undergoing repeated phlebotomies. The FDA drug label for hydroxyurea explicitly states that "prophylactic administration of folic acid is recommended" 1.
Rationale for Folic Acid Supplementation
Hydroxyurea-Induced Macrocytosis
Hydroxyurea causes macrocytosis as a known side effect, which appears early in treatment and is self-limiting 1. This morphologic change resembles pernicious anemia but is not related to vitamin B12 or folic acid deficiency. However, this macrocytosis can mask the diagnosis of true pernicious anemia if it develops 1.
The key concern: While hydroxyurea-induced macrocytosis isn't caused by folate deficiency, the FDA specifically recommends prophylactic folic acid to prevent this complication from obscuring a genuine folate or B12 deficiency that could develop independently.
Increased Folate Demands in PV
Patients with polycythemia vera face multiple factors that increase folate requirements:
- Repeated phlebotomies create ongoing demand for red blood cell production
- Hydroxyurea therapy interferes with DNA synthesis and cell division
- Chronic myeloproliferation inherent to PV increases cellular turnover
The combination of these factors creates a scenario where folate stores could become depleted over time, particularly with the frequent phlebotomies needed to maintain hematocrit <45% 2, 3.
Clinical Practice Implications
When to Prescribe
Initiate folic acid supplementation:
- At the start of hydroxyurea therapy (prophylactic approach per FDA label)
- Continue throughout treatment with hydroxyurea
- Maintain during periods of frequent phlebotomy
Dosing
Standard supplementation is typically 1 mg daily (though the FDA label doesn't specify exact dosing, this is standard clinical practice for prophylaxis).
Monitoring Considerations
While folic acid supplementation is recommended, you should still:
- Monitor complete blood counts weekly initially, then as clinically indicated 1
- Evaluate for true megaloblastic anemia if macrocytosis worsens or anemia develops
- Check B12 levels if clinical suspicion for deficiency arises, as folic acid alone won't correct B12 deficiency
Important Caveats
The evidence base is limited: The FDA recommendation is based on the mechanism of hydroxyurea-induced macrocytosis rather than robust clinical trial data showing improved outcomes with folic acid supplementation. One small study in sickle cell disease patients on hydroxyurea found no benefit from folic acid 4, but this population differs significantly from PV patients undergoing repeated phlebotomies.
No harm in supplementation: Given the low cost, excellent safety profile, and explicit FDA recommendation, the risk-benefit ratio strongly favors supplementation even in the absence of definitive outcome data.
The European LeukemiaNet guidelines [3-3] and ESMO guidelines 2 don't specifically address folic acid supplementation, focusing instead on cytoreductive therapy and thrombosis prevention. However, the absence of guideline discussion doesn't negate the FDA drug label recommendation, which takes precedence for medication-specific management.